AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 212 min read$ABT

Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition

Abbott Laboratories (ABT) reported Q3 adjusted EPS of $1.42, with revenue up 14.5% YoY to $13.01B. Q4 EPS guidance met expectations, but full-year 2026 sales growth forecast was lowered to ~6%. The company plans to spin off its Nutrition business by the end of 2027, aiming to focus on higher-growth healthcare sectors. Medical Devices and Diagnostics saw strong growth, while Diabetes Care faced reimbursement challenges.

Original reporting
gurufocus.com
Published Oct 21, 2026, 5:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 5:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ABTBearishHigh
01

Why it matters

The earnings release shows solid segment performance but a weaker outlook, prompting a likely sell‑off. The announced Nutrition spin‑off adds strategic complexity and could create a new investment opportunity.

02

Market read

First‑time reporting of Q3 results, guidance cut, and spin‑off plan makes this a high‑impact earnings news item for traders.

03

What to watch

Abbott's strong Diagnostics growth and recent Exact Sciences acquisition may provide upside that the article downplays.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Abbott Laboratories is a diversified health‑care company with segments in Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott reported Q3 earnings with adjusted EPS $1.42 and cut full-year comparable sales growth outlook, while announcing a spin‑off of its Nutrition business.

Expected impact

downward pressure as investors price in lower sales growth and uncertainty around the Nutrition separation.

Evidence & confidence

Guidance cut and a major restructuring are material catalysts for a large‑cap health‑care stock.

Market effects

Sector

The cut in sales growth may pressure other diversified health‑care peers, while the Nutrition spin‑off could create a new pure‑play nutrition company.

Regional

U.S. health‑care sector may see modest downside as investors reassess growth assumptions.

Global

Limited; primarily affects U.S. and global health‑care investors tracking Abbott.

Counterpoint

What could challenge this read

The spin‑off could unlock value if the Nutrition unit operates as a focused consumer‑health business, potentially offsetting short‑term earnings concerns.

Key entities

  • company
    Abbott Laboratories

    U.S.-listed health‑care conglomerate (ticker ABT).

Read at source← All news

StoryAbbott to spin off Nutrition unit into independent public company by late 2027

Also covered by

4 outlets

Related articles

OCT 21
$ABTHighAI 8/10

Abbott options flow points to downside caution after guidance cut

Abbott Laboratories (ABT) shares fell 3.56% to $98.80 after Q3 results met EPS estimates and slightly beat revenue forecasts, but full-year sales growth guidance was lowered to 6%. Options flow showed a defensive tilt with 58% puts, including a diagonal put spread of 2,224 contracts. Implied volatility and downside put costs decreased, suggesting the market has priced in the earnings reset.

investing.com2 min
OCT 21
$RTXHighAI 8/10

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq Composite and Russell 2000 led a three-day market rally, with Nasdaq up 2.14% and Russell 2000 up 2.36% for the week. The Dow and S&P 500 also gained over 1.2%. Several companies reported earnings, including RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group (Nasdaq: CME), M/I Homes (NYSE: MHO), and Lockheed Martin (NYSE: LMT). RTX reported $25.0B in Q3 sales and raised its full-year outlook. Abbott posted 14.5% sales growth. CME Group saw record Q3 revenue.

prnewswire.com3 min
OCT 21
$ABTMedAI 8/10

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call

Abbott Laboratories (ABT) reported Q3 comparable sales up 7% and adjusted EPS of $1.42, in line with guidance. The company expects sales growth to accelerate post-nutrition separation and forecasts Q4 adjusted EPS of $1.62-$1.67. Abbott also provided updates on its medical device pipeline and near-term pressures in electrophysiology and diabetes care.

finance.yahoo.com3 min
OCT 21
$ABTMedAI 8/10

Abbott Laboratories Q3 2026 Earnings Call Summary

Abbott Laboratories reported Q3 2026 sales growth of 7%, driven by diagnostics and electrophysiology. The company plans to separate its nutrition business by late 2027, aiming for accelerated sales and margin growth. Q4 guidance includes a temporary headwind in the LAA market. Management expects continued growth in 2027, with new product launches. The nutrition spin-off is expected to be tax-free, with both entities maintaining strong capital positions.

finance.yahoo.com3 min
OCT 21
$ABTMed

Abbott plans to spin out its nutrition business

Abbott plans to spin off its nutrition business, which has $8.5B annual sales, into a separate publicly traded company by late 2027. The move aims to focus on higher-growth markets. Abbott's Q3 revenue was $13.01B, with nutrition contributing $2.26B. The spinout is not expected to impact 2026-2027 guidance. Abbott faces ongoing litigation related to its nutrition business.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories earnings analysis: questions answered and next catalysts

Abbott Laboratories (ABT) reported Q3 2026 earnings matching expectations, with revenue of $13.01B and adjusted EPS of $1.42. The stock fell 3.42% due to a guidance cut, trimming full-year sales growth to 6%. Diagnostics and nutrition sales grew, but electrophysiology and diabetes care slowed. Management plans to separate the nutrition business. Next catalysts include Libre Duo launch, payer formulary changes, and Q4 results.

investing.com2 min